Table 4.
Study groups |
|||
---|---|---|---|
3 n = 86 |
4 n = 81 |
5 n = 23 |
|
Age (years)* | 38.0 ± 10.0a | 46.1 ± 9.9b | 46.3 ± 10.9b |
BMI (kg/m2)** | 30.6 ± 4.6 | 30.7 ± 4.7 | 32.6 ± 5.0 |
WC (cm)** | 98.7 ± 11.2a | 100.6 ± 11.0ab | 103.5 ± 8.7b |
SBP (mm Hg)* | 112.2 ± 12.0a | 113.8 ± 15.9a | 127.0 ± 13.3b |
DBP (mm Hg)* | 75.5 ± 9.3a | 76.5 ± 9.4a | 84.3 ± 7.7b |
Gluc0h (mg/dL)** | 100.7 ± 27.3a | 109.1 ± 26.6b | 109.5 ± 7.6c |
Gluc2h (mg/dL)** | 129.9 ± 53.3a | 150.1 ± 60.6b | 169.7 ± 44.7c |
Ins0h (μIU/mL)** | 11.5 ± 5.9 | 11.8 ± 5.6 | 13.5 ± 6.4 |
Ins2h (μIU/mL)** | 77.1 ± 57.1a | 87.6 ± 67.2ab | 114.0 ± 85.6b |
HOMA-IR** | 2.9 ± 2.0a | 3.2 ± 1.7ab | 3.7 ± 1.8b |
HOMA-β** | 129.2 ± 73.3a | 103.5 ± 48.1b | 104.1 ± 52.3ab |
QUICKI* | 0.34 ± 0.03a | 0.33 ± 0.02ab | 0.32 ± 0.02b |
TC (mg/dL)** | 191.2 ± 37.5a | 208.3 ± 44.5b | 214.4 ± 43.6b |
HDL-C (mg/dL)** | 35.6 ± 9.8a | 38.4 ± 7.3b | 37.6 ± 6.6ab |
LDL-C (mg/dL)** | 120.5 ± 30.3 | 126.1 ± 42.9 | 130.9 ± 35.7 |
VLDL-C (mg/dL)** | 35.1 ± 15.9a | 43.7 ± 18.3b | 45.8 ± 15.9b |
TAG (mg/dL)** | 175.7 ± 79.5a | 218.7 ± 91.6b | 229.2 ± 79.3b |
TAG/HDL-C** | 5.3 ± 2.8 | 6.1 ± 3.3 | 6.3 ± 2.3 |
CVI** | 5.6 ± 1.4 | 5.6 ± 1.3 | 5.8 ± 1.1 |
Notes: Results are expressed as mean ± standard deviation.
P # 0.05, one-way analysis of variance/Tukey–Kramer;
P # 0.05, Kruskal–Wallis one-way analysis of variance/Kruskal–Wallis multiple comparisons. Different letters (a, b, c) in a row indicate significant difference (P # 0.05) between groups.
Abbreviations: NCEP ATP-IIIm, third expert panel of the national cholesterol education program-modified; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; Glc0h, fasting glucose; Gluc2h, Glucose 2 hours after a 75-g of glucose oral load; Ins0h, fasting insulin; Ins2h, insulin 2 hours after 75-g of oral glucose load; TC, total cholesterol; HDL-C, cholesterol combined with high-density lipoprotein; LDL-C, cholesterol combined with low-density lipoprotein; VLDL-C, cholesterol combined with very low-density lipoprotein; TAG, triacylglycerides; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-β, homeostatic model assessment of β-cell function; QUICKI, index to check the quantitative insulin sensitivity; CVI, Castelli Cardiovascular Index.